• Aucun résultat trouvé

[PDF] Top 20 Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.: Areg and gefitinib resistance in NSCLC

Has 10000 "Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.: Areg and gefitinib resistance in NSCLC" found on our website. Below are the top 20 most common "Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.: Areg and gefitinib resistance in NSCLC".

Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.: Areg and gefitinib resistance in NSCLC

Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.: Areg and gefitinib resistance in NSCLC

... Molecular resistance mechanisms affecting the efficiency of receptor tyrosine kinase inhibitors such as gefitinib in Non-Small Cell Lung Cancer (NSCLC) cells are ... Voir le document complet

34

en
                                                                    fr

en fr IDENTIFICATION AND CHARACTERIZATION OF AN ORIGINAL MECHANISM OF RESISTANCE TO GEFITINIB IN NON-SMALL LUNG CANCERS: ROLE OF AMPHIREGULIN IDENTIFICATION ET CARACTÉRISATION D'UN NOUVEAU MÉCANISME DE RÉSISTANCE AU GEFITINIB DANS LE CANCER DU POUMON NON-À PETITES CELLULES : ROLE DE L'AMPHIRÉGULINE

... Notre équipe travaille depuis plusieurs années sur le développement de nouveaux traitements des CBNPC destinés à rétablir les voies d’induction de l’apoptose ou à réguler la prolifération non contrôlée de ces ... Voir le document complet

106

Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.

Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.

... RNAi and pharmacological inhibition. First, H358 and H1650 cells were much more sensitive to simultaneous inhibition by RNAi of both EGFR and c-MET pathways, but less effect was ... Voir le document complet

11

Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells.

Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells.

... AR and IGF1 are the key anti-apoptotic molecules in the conditioned medium from H358 cells and that the cooperation of those growth factors inhibits apoptosis via both IGF1 and EGF receptors ... Voir le document complet

18

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism

... overexpressed in nonsmall-cell lung cancers (NSCLCs) and is associated with a poor ...gefitinib and erlotinib) have been developed, and are highly effective for the ... Voir le document complet

14

The increasing role of amphiregulin in non-small cell lung cancer.

The increasing role of amphiregulin in non-small cell lung cancer.

... fact, AREG is involved in NSCLC resistance to ...EGFR-TKI. Gefitinib responders and non-responders present a differential expression of AREG gene in ... Voir le document complet

10

A synthetic eIF4E1 resistance allele allows resistance pyramiding and broad resistance spectrum to potyviruses in Arabidopsis thaliana

A synthetic eIF4E1 resistance allele allows resistance pyramiding and broad resistance spectrum to potyviruses in Arabidopsis thaliana

... C. and Gallois, J.L. (2016) A TILLING approach to generate broad-spectrum resistance to potyviruses in tomato is hampered by eIF4E gene ... Voir le document complet

2

Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

... receptor and multiple cofactors (for recent reviews [9, ...defined and complex sequential program initiated by recruitment of coactivators and corepressors [56, ...NCOR1 and SMRT or ... Voir le document complet

34

The use of bevacizumab in non-small cell lung cancer: an update.

The use of bevacizumab in non-small cell lung cancer: an update.

... of NSCLC is undergoing significant progress due to the continuous evolution of chemotherapy drugs and the introduction of new targeted ...advanced, and their general clinical condition (2). ... Voir le document complet

9

Small RNAs in vancomycin-resistant Enterococcus faecium involved in daptomycin response and resistance

Small RNAs in vancomycin-resistant Enterococcus faecium involved in daptomycin response and resistance

... included, in the future, in a new resource for the hundreds of sRNAs identified in gram-positive bacteria 63 , as recently documented for staphylococci 47 ...exposure, and their possible ... Voir le document complet

14

p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.

p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.

... L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ... Voir le document complet

3

Efficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study

Efficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study

... found in DCR between pts treated in 2nd and 3rd line but some subgroups may derive a greater survival benefit when receiving erlotinib 2nd ... Voir le document complet

1

Cell-Intrinsic and cell-extrinsic resistance to classical chemotherapies

Cell-Intrinsic and cell-extrinsic resistance to classical chemotherapies

... challenge to changing the current standard of care is the poor efficacy of current ...Due to that fact, and differences in the regulatory environment, clinicians were able to rapidly ... Voir le document complet

121

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

... processes in breast carcinogenesis (apoptosis, cell cycle, signalling pathways, angiogenesis, DNA repair, drug resistance) (Table 2 ...cultured in 10 mm dishes and treated with 5 µM ... Voir le document complet

13

Étude des mécanismes de résistance au gefitinib dans le cancer du poumon non-à petites cellules‎ : rôle des HDAC

Étude des mécanismes de résistance au gefitinib dans le cancer du poumon non-à petites cellules‎ : rôle des HDAC

... le gefitinib ont été ...bronchique non à petites cellules (CBNPC), ne sont pas pleinement ...par gefitinib et médiée par l’amphiréguline dans les cellules de ...le gefitinib et l’inhibition ... Voir le document complet

127

Temperature Measurements in Fire Resistance Tests on Small-Scale, Insulated and Non-Insulated, Regular Gypsum Board Assemblies

Temperature Measurements in Fire Resistance Tests on Small-Scale, Insulated and Non-Insulated, Regular Gypsum Board Assemblies

... Access and use of this website and the material on it are subject to the Terms and Conditions set forth at Temperature Measurements in Fire Resistance Tests on ... Voir le document complet

77

In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients

In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients

... response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer ...its in-house assessment in routine clinical practice is currently ... Voir le document complet

14

Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria

Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria

... IS1F-like and ISKpn14 elements belonging to several IS families (especially the IS5 family), have been observed to lead to the truncation of ...observed to transposed to the ... Voir le document complet

19

Trends in Response Rate and Survival in Small-Cell Lung Cancer Patients Between 1997 and 2017

Trends in Response Rate and Survival in Small-Cell Lung Cancer Patients Between 1997 and 2017

... ORR to first-line CT (mostly etoposide and platinum) was ...67% in patients treated with cisplatin and 66% in those treated with carboplatin in the Rossi study ...as in a ... Voir le document complet

39

Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels

Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels

... for non-smallcell lung cancer (NSCLC) is ...advanced and locally advanced disease ...Criteria In Solid Tumours (RECIST) version 1.1 [2]. However, in the setting of ICI these ... Voir le document complet

5

Show all 10000 documents...